Osiris Regains Prochymal via Public Brushoff from Sanofi

The breakup of a $1.38 billion stem cell partnership between Genzyme Corp. and Osiris Therapeutics Inc., dating to 2008, was heralded by an offhand mention in a Sanofi SA post-Genzyme-acquisition pipeline update, sending the biotech's shares down 15 percent Thursday.